Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy
- Status
- UNKNOWN
- Phase
- PHASE2
Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
- Status
- TERMINATED
- Phase
- PHASE2
Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC
- Status
- COMPLETED
- Phase
- PHASE2
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
- Status
- UNKNOWN
- Phase
- PHASE1
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
- Status
- TERMINATED
- Phase
- PHASE2
Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE3
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
- Status
- COMPLETED
- Phase
- PHASE1
Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
- Status
- UNKNOWN
- Phase
- PHASE2
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
- Status
- COMPLETED
- Phase
- PHASE2
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1